Chattem - A consumer healthcare platform in the United-States
The acquisition of Chattem and its recognized brands strengthens sanofi-aventis’ position in the world's consumer healthcare arena and opens the doors to the U.S market. The addition of Chattem represents an important milestone in sanofi-aventis’ strategy to become a global diversified healthcare leader. This acquisition will also provide a new platform that will allow for the conversion of sanofi-aventis’ prescription medicines to over-the-counter products. The first conversion is expected to be Allegra® (fexofenadine hydrochloride), an antihistamine to relieve seasonal allergy symptoms, in the U.S.